NYSEAMERICAN:AIM AIM ImmunoTech (AIM) Stock Price, News & Analysis $0.26 +0.01 (+3.36%) As of 08/28/2026 04:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About AIM ImmunoTech Stock (NYSEAMERICAN:AIM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AIM ImmunoTech alerts:Sign Up Key Stats Today's Range$0.25▼$0.2650-Day Range$0.22▼$0.3852-Week Range$0.19▼$2.98Volume325,610 shsAverage Volume1.57 million shsMarket Capitalization$7.87 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingBuy Company Overview AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments. In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats. AIM ImmunoTech has collaborated with government agencies and academic institutions to support its clinical development, leveraging these partnerships to access specialized expertise and streamline regulatory pathways. Headquartered in Ocala, Florida, AIM ImmunoTech conducts its research and manufacturing operations in the United States, while seeking to establish strategic collaborations that extend its global reach. The company’s management team comprises experienced professionals in biotechnology development, regulatory affairs and commercial strategy, with a shared commitment to bringing novel immunotherapeutic solutions to market. AI Generated. May Contain Errors. Read More AIM ImmunoTech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks67th Percentile Overall ScoreAIM MarketRank™: AIM ImmunoTech scored higher than 67% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingAIM ImmunoTech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 1 buy rating, 1 hold rating, and no sell ratings.Upside PotentialAIM ImmunoTech has a consensus price target of $9.00, representing about 3,383.0% upside from its current price of $0.26.Amount of Analyst CoverageAIM ImmunoTech has only been the subject of 1 research reports in the past 90 days.Read more about AIM ImmunoTech's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for AIM ImmunoTech are expected to grow in the coming year, from ($0.63) to ($0.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AIM ImmunoTech is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AIM ImmunoTech is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAIM ImmunoTech has a P/B Ratio of 1.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.29% of the float of AIM ImmunoTech has been sold short.Short Interest Ratio / Days to CoverAIM ImmunoTech has a short interest ratio ("days to cover") of 0.34, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AIM ImmunoTech has recently decreased by 24.33%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAIM ImmunoTech does not currently pay a dividend.Dividend GrowthAIM ImmunoTech does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.40 News SentimentAIM ImmunoTech has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.94 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for AIM ImmunoTech this week, compared to 3 articles on an average week.Search Interest14 people have searched for AIM on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.MarketBeat Follows2 people have added AIM ImmunoTech to their MarketBeat watchlist in the last 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, AIM ImmunoTech insiders have not sold or bought any company stock.Percentage Held by Insiders0.95% of the stock of AIM ImmunoTech is held by insiders.Percentage Held by Institutions12.02% of the stock of AIM ImmunoTech is held by institutions.Read more about AIM ImmunoTech's insider trading history. Receive AIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AIM ImmunoTech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AIM Stock News HeadlinesÉléments financiers clés - AIMAugust 29 at 12:03 AM | fr.investing.comAIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand ConferenceAugust 27 at 3:04 PM | finance.yahoo.comWhy Boston Ships In Natural Gas It Already Has at HomeA tanker called the Iberica Knutsen once sailed 2,272 miles from Trinidad and Tobago to deliver liquefied natural gas to Boston. The odd part: the Marcellus Shale, one of the largest natural gas reserves in the world, sits just a few hundred miles away. Porter Stansberry spent years digging into why this happens and what it means for the American energy system.August 30 at 1:00 AM | Porter & Company (Ad)AIM ImmunoTech Participates in the Virtual Investor 'Why Now' On-Demand ConferenceAugust 27 at 9:20 AM | tmcnet.comAIM ImmunoTech Participates in the Virtual Investor ‘Why Now' On-Demand ConferenceAugust 27 at 9:01 AM | globenewswire.comAnalysts Are Bullish on Top Healthcare Stocks: AIM ImmunoTech (AIM), Niagen Bioscience (NAGE)August 26, 2026 | theglobeandmail.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: AIM ImmunoTech (AIM) and Schrodinger (SDGR)August 13, 2026 | theglobeandmail.comAIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ ArticleAugust 12, 2026 | markets.businessinsider.comSee More Headlines AIM Stock Analysis - Frequently Asked Questions How have AIM shares performed this year? AIM ImmunoTech's stock was trading at $1.1289 at the beginning of 2026. Since then, AIM stock has decreased by 77.1% and is now trading at $0.2584. How were AIM ImmunoTech's earnings last quarter? AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) issued its earnings results on Friday, August, 7th. The company reported ($0.43) EPS for the quarter. The company had revenue of $0.03 million for the quarter. When did AIM ImmunoTech's stock split? AIM ImmunoTech shares reverse split before market open on Thursday, June 12th 2025.The 1-100 reverse split was announced on Wednesday, June 11th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 11th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of AIM ImmunoTech? Shares of AIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AIM ImmunoTech own? Based on aggregate information from My MarketBeat watchlists, some other companies that AIM ImmunoTech investors own include Gold Resource (GORO), 36Kr (KRKR), Ocean Power Technologies (OPTT), Aemetis (AMTX), Avino Silver & Gold Mines (ASM), eMagin (EMAN) and EMX Royalty (EMX). Company Calendar Last Earnings8/07/2026Today8/30/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSEAMERICAN:AIM Previous SymbolNYSEAMERICAN:HEB CIK946644 Webaimimmuno.com Phone(352) 448-7797Fax215-988-1739Employees20Year Founded1990Price Target and Rating Average Price Target for AIM ImmunoTech$9.00 High Price Target$9.00 Low Price Target$9.00 Potential Upside/Downside+3,383.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($24.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.96 million Net Margins-15,021.05% Pretax Margin-15,021.05% Return on EquityN/A Return on Assets-143.02% Debt Debt-to-Equity RatioN/A Current Ratio2.11 Quick Ratio2.11 Sales & Book Value Annual Sales$90 thousand Price / Sales87.40 Cash FlowN/A Price / Cash FlowN/A Book Value$0.25 per share Price / Book1.03Miscellaneous Outstanding Shares30,440,000Free Float30,153,000Market Cap$7.87 million OptionableNot Optionable Beta1.20 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NYSEAMERICAN:AIM) was last updated on 8/30/2026 by MarketBeat.com Staff. From Our PartnersThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredA $382 trillion migration and the position no one is talking aboutTrump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...Awesomely | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredSPDR Gold just lost $14 billion.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...Behind the Markets | SponsoredHormuz tanker traffic collapses as the oil crisis deepensTanker traffic through Hormuz has plunged from 110-130 daily transits to near zero, while 17% of Qatar's LNG c...Golden Portfolio | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]In 1999, George Gilder predicted phones would outpower desktop computers. Apple's iPhone followed, and the sto...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AIM ImmunoTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AIM ImmunoTech With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
